Welcome to our dedicated page for Liquidia Corporation news (Ticker: LQDA), a resource for investors and traders seeking the latest updates and insights on Liquidia Corporation stock.
Liquidia Corporation (NASDAQ: LQDA) is a biopharmaceutical company focused on therapies for rare cardiopulmonary disease, particularly pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH‑ILD). News about Liquidia often centers on its treprostinil‑based portfolio, including YUTREPIA™ (treprostinil) inhalation powder, the investigational L606 treprostinil liposome inhalation suspension, and its role in promoting generic Treprostinil Injection in the United States.
On this page, readers can follow company announcements related to YUTREPIA’s commercial launch, prescription trends and patient starts, as well as updates from ongoing clinical programs such as the ASCENT study in PH‑ILD. Liquidia regularly reports interim clinical data, including safety and exploratory efficacy findings, and provides context on how these results may inform treatment of PAH and PH‑ILD.
Investors and observers will also find coverage of quarterly financial results, revenue contributions from YUTREPIA and Treprostinil Injection, and details of corporate developments disclosed in press releases and SEC filings. These include financing arrangements, manufacturing expansion in Morrisville, North Carolina, and licensing agreements such as the exclusive U.S. license with Vectura for a nebulizer device used with L606.
In addition, Liquidia frequently participates in medical and investor conferences, R&D days and scientific meetings, where it presents new data on YUTREPIA and L606 and discusses its strategy in pulmonary hypertension. This news feed helps track how Liquidia advances its PRINT®‑enabled inhaled therapies, navigates litigation and regulatory milestones, and communicates with the medical and investment communities over time.
Liquidia Technologies, Inc. (NASDAQ: LQDA) announced a public offering of 9,375,000 shares of common stock at $8.00 each, yielding gross proceeds of $75 million. This offering is solely by Liquidia, with a 30-day option for underwriters to purchase an additional 1,406,250 shares. The transaction is expected to close on July 2, 2020. Jefferies serves as the sole book-running manager. The offering is conducted under a shelf registration statement declared effective by the SEC in September 2019, and related documents can be accessed via the SEC website.
Liquidia Technologies (NASDAQ: LQDA) has announced its acquisition of RareGen, LLC, enhancing its capabilities in pulmonary arterial hypertension (PAH) treatment. The all-stock merger, expected to close in Q4 2020, will create Liquidia Corporation and allow it to promote RareGen's generic treprostinil. This strategic move is aimed at improving the company's commercial readiness for LIQ861, an inhaled treatment for PAH. The merger is set to bolster Liquidia's market presence, integrating RareGen's sales force and expertise in rare diseases.
Liquidia Technologies (LQDA) has announced a patent infringement lawsuit filed by United Therapeutics Corporation against it, relating to its New Drug Application (NDA) for LIQ861, a dry powder inhalation of treprostinil for pulmonary arterial hypertension (PAH). The case, filed under the Hatch-Waxman Act, could delay FDA approval of LIQ861 by up to 30 months. Liquidia asserts that the patents are either invalid or not infringed and intends to defend against the suit vigorously. The company has previously filed petitions for inter partes review of the patents, with a decision expected by Q3 2020.
Liquidia Technologies (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company, announced that CEO Neal Fowler will present an overview at the Jefferies Virtual Healthcare Conference on June 2, 2020, at 10:30 AM ET. The event will be accessible via a live audio webcast, available on the company’s website and archived for 90 days. Liquidia focuses on developing novel products using its proprietary PRINT® technology, aiming to enhance therapy safety and efficacy. Notable product candidates include LIQ861 for pulmonary arterial hypertension and LIQ865 for post-operative pain.
Liquidia Technologies (LQDA) announced the appointment of Dr. Tushar Shah as Chief Medical Officer. Dr. Shah brings 27 years of experience in pharmaceutical research, overseeing clinical development activities. His previous roles include Head of Global Specialty Clinical Development at Teva Pharmaceuticals. This leadership change is expected to enhance Liquidia's capabilities, particularly as it advances LIQ861 (pending NDA review) and LIQ865 (currently in clinical development), utilizing Liquidia's proprietary PRINT technology.
Liquidia Technologies, Inc. (LQDA) will announce its first quarter 2020 financial results on May 11, 2020, at 4:30 p.m. ET. The company plans to host a webcast and conference call to discuss these results and provide a corporate update.
Liquidia is focused on developing novel biopharmaceutical products using its proprietary PRINT® technology, with two primary candidates: LIQ861 for pulmonary arterial hypertension and LIQ865 for post-operative pain treatment.
Summary not available.